Flagship Harbor Advisors’s Sarepta Therapeutics SRPT Stock Holding History

Flagship Harbor Advisors’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-49	Closed	-$1.05K	–	1995
2025 Q4	$1.05K	Buy	+49	New	+$1.03K	﹤0.01%	1934
2020 Q4	–	Sell	-156	Closed	-$21K	–	1594
2020 Q3	$21K	Hold	156	–	–	﹤0.01%	1132
2020 Q2	$25K	Buy	156 +45	+41%	+$6.12K	﹤0.01%	1075
2020 Q1	$11K	Hold	111	–	–	﹤0.01%	1209
2019 Q4	$14K	Hold	111	–	–	﹤0.01%	1241
2019 Q3	$8K	Sell	111 -45	-29%	-$5.31K	﹤0.01%	1360
2019 Q2	$23K	Buy	156 +30	+24%	+$3.65K	﹤0.01%	1024
2019 Q1	$15K	Sell	126 -50	-28%	-$6.43K	﹤0.01%	1174
2018 Q4	$19K	Hold	176	–	–	﹤0.01%	1044
2018 Q3	$26K	Sell	176 -35	-17%	-$4.79K	﹤0.01%	1041
2018 Q2	$27K	Buy	+211	New	+$19.9K	0.01%	1009

Other funds holding SRPT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Flagship Harbor Advisors's SRPT Position: Q1 2026 in Review

Flagship Harbor Advisors sold out of Sarepta Therapeutics (SRPT) in Q1 2026, closing a stake of 49 shares — an estimated $1.05K sold.

Flagship Harbor Advisors first reported a position in SRPT in Q2 2018 and held it in 11 quarters. The position peaked at $27K in Q2 2018. 345 funds tracked by Wall St. Rank hold SRPT as of Q1 2026.

Flagship Harbor Advisors reported no remaining Sarepta Therapeutics position as of Q1 2026 after selling out during the quarter.
Flagship Harbor Advisors sold 49 Sarepta Therapeutics shares in Q1 2026, an estimated $1.05K.
Flagship Harbor Advisors first reported a position in Sarepta Therapeutics in Q2 2018 and held it in 11 quarters.
Flagship Harbor Advisors's Sarepta Therapeutics position peaked at $27K in Q2 2018.
345 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2026.

Based on Flagship Harbor Advisors's 13F filing for Q1 2026, filed 28 Apr 2026.